Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management
- PMID: 16107109
- PMCID: PMC1163465
Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management
Abstract
Amyloidosis comprises a unique group of diseases that share in common the extracellular deposition of insoluble fibrillar proteins in organs and tissues. Cardiovascular amyloidosis can be primary, a part of systemic amyloidosis, or a result of chronic systemic diseases elsewhere in the body. The most common presentations are congestive heart failure-mainly a restrictive infiltrative pattern--and conduction system disturbances. Recent developments in imaging techniques and extracardiac tissue sampling have minimized the need for invasive endomyocardial biopsy for amyloidosis. Despite advances in treatment, the prognosis for patients with amyloidosis is still poor and depends on the underlying disease type. Herein, we present new insights and recent advances in cardiovascular amyloidosis.
Figures
References
-
- Kyle RA. Amyloidosis: a convoluted story. Br J Haematol 2001;114:529–38. - PubMed
-
- Smith RR, Hutchins GM, Moore GW, Humphrey RL. Type and distribution of pulmonary parenchymal and vascular amyloid. Correlation with cardiac amyloid. Am J Med 1979;66:96–104. - PubMed
-
- Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000;130:88–98. - PubMed
-
- Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898–909. - PubMed
-
- Benson MD. Amyloidosis. In: Scriver CR, editor. The metabolic and molecular bases of inherited disease. Vol 1. 8th ed. New York: McGraw-Hill; 2001. p. 5345–8.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical